PI Industries Limited — Investor Meet, 19-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

PI Industries' Q2 FY26 revenue was Rs. 1872.3 Cr, down 16%, with H1 revenue off 12%. Global agchem weakness, erratic rains, and temporary biological regulatory issues impacted results. Pharma revenue, a highlight, grew 54%. Management projects a Q4 FY26 recovery in AgChem exports and a positive Rabi outlook. Five new AgChem molecules launched, driving 38% H1 new product export growth. Pharma & biologicals are in investment phase for long-term expansion. The $1.25 billion order book supports strategic diversified growth across life sciences.